Choices in Adjuvant Therapy of Melanoma
Open Access
- 1 October 2005
- journal article
- review article
- Published by SAGE Publications in Cancer Control
- Vol. 12 (4), 236-241
- https://doi.org/10.1177/107327480501200405
Abstract
High-dose interferon (IFN) is the approved agent for adjuvant treatment of melanoma in the United States. This approval is for high-risk, predominantly stage III patients with cutaneous primaries. There are still decisions to be made in the care of these patients. Also, there are questions about whether the IFN data can be extrapolated to patients with other stages of melanoma and whether adjuvant treatment should be offered to these individuals. Clearly there is room for improvement in this area. The literature on this topic and ongling national trials in the United States were reviewed. The data are insufficient to recommend other agents in the adjuvant treatment of melanoma outside a clinical trial. Extrapolation of the IFN data to patient populations other than those studied is problematic at best. National trials are available for most patient populations. The adjuvant treatment of choice for melanoma patients is participation in a clinical trial.Keywords
This publication has 24 references indexed in Scilit:
- A Pooled Analysis of Eastern Cooperative Oncology Group and Intergroup Trials of Adjuvant High-Dose Interferon for MelanomaClinical Cancer Research, 2004
- Adjuvant Interferon Therapy for Melanoma: High-Dose, Low-Dose, No Dose, Which Dose?Journal of Clinical Oncology, 2004
- Present Status and Future Prospects for Adjuvant Therapy of Melanoma: Time to Build upon the Foundation of High-dose Interferon Alfa-2bJournal of Clinical Oncology, 2004
- Pros and Cons of Adjuvant Interferon in the Treatment of MelanomaThe Oncologist, 2003
- Does adjuvant interferon-α for high-risk melanoma provide a worthwhile benefit? A meta-analysis of the randomised trialsCancer Treatment Reviews, 2003
- Adjuvant High-Dose Bolus Interleukin-2 for Patients With High-Risk Renal Cell Carcinoma: A Cytokine Working Group Randomized TrialJournal of Clinical Oncology, 2003
- Prospective Randomized Trial of Interferon Alfa-2b and Interleukin-2 as Adjuvant Treatment for Resected Intermediate- and High-Risk Primary Melanoma Without Clinically Detectable Node MetastasisJournal of Clinical Oncology, 2003
- Malignant melanoma: current state of primary and adjuvant treatmentCritical Reviews in Oncology/Hematology, 2003
- Durability of Complete Responses in Patients With Metastatic Cancer Treated With High-Dose Interleukin-2Annals of Surgery, 1998
- Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684.Journal of Clinical Oncology, 1996